NCT01584843已完成3 期
A Multicenter, Randomized, Evaluator-masked, Parallel-group, Non-treatment-controlled Study Followed by an Open-label Study to Evaluate Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- Change From Baseline in Strabismus Angle Prism Dioptre (PD) in the Primary Position at Week 4 of the FTP in Observed Cases (OC)
研究概览
简要总结
Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820 compared with non-treatment in patients with strabismus based on angles of strabismus in the primary position.
详细描述
Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820 compared with non-treatment in patients with strabismus based on angles of strabismus in the primary position. Secondary objective is to evaluate the efficacy and safety of repeated-dose treatment with GSK1358820 in patients with strabismus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •<At the start of screening period>
- •Paralytic or concomitant strabismus. Subjects with paralytic strabismus will be eligible for inclusion only if paralysis has persisted for at least 3 months and strabismus has been developed at one eye
- •Horizontal deviations (esotropia or exotropia)
- •Strabismus with the (absolute) strabismus angles at both distance and near of primary position >-10 PD and <50 PD
- •Age>-12 years at the time of giving informed consent
- •The subject has to be capable of giving written informed consent of their own will. For subjects aged less than 20 years, the subject and his/her legally acceptable representative (person in parental authority or guardian) have to give written informed consent
- •Either sex. Males have to agree to practice contraception during the study period. Females of child-bearing potential will be eligible for inclusion in this study. However, they have to have negative pregnancy test both at the screening visit and just before initial injection and agree to practice reliable methods of contraception
- •QTc <450 msec; for patients with Bundle Branch Block, QTc <480 msec based on average QTc value of triplicate ECGs <At the start of treatment period >
- •Strabismus with the (absolute) strabismus angles at both distance and near of primary position >-10 PD and <50 PD
- •ALT at the screening visit <2 x ULN and alkaline phosphatase and bilirubin <-1.5 x ULN
排除标准
- •<At the start of screening period>
- •Secondary strabismus caused by prior surgical recession of the antagonist in past surgical treatment of strabismus
- •Strabismus due to abnormal innervations
- •Strabismus with thyroid-associated ophthalmopathy
- •Strabismus with strong motor limitation of extraocular muscles
- •Mechanical limitations of ocular movement due to periorbital disease or due to past surgical treatment other than strabismus
- •Blepharoptosis
- •Conjunctival pathology
- •Systemic neuromuscular junction dysfunction
- •Systemic neuromuscular disease
- •Past treatment with botulinum toxin
- •Planned injections of botulinum toxin for other indication(s) or for cosmetic purpose during the study period
- •Known hypersensitivity to any of the drugs to be used in the study or history of allergy
- •Treatment with antibiotics with neuromuscular junction inhibitory action such as aminoglycosides, polypeptides, tetracyclines and lincomycins, except those contained in topical antibacterial formulations
- •Treatment with muscle relaxants or drugs with muscle relaxant action
- •Chronic respiratory disorder
- •Severe muscle weakness or atrophy
- •Angle-closure glaucoma or its predisposing factors
- •Severe cardiac, hepatic or renal impairment. The severity refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences" (MHLW PAB/SD Notification No. 80, dated 29 June 1992).
- •Surgical operation or hospitalization to be needed during the study period
- •Female subjects who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study period
- •Participation in another clinical study within 6 months prior to enrollment in this study or planned participation in another clinical study after enrollment in this study
- •Psychiatric disorder or impairment of intellectual function that may affect the subject's ability to give informed consent or to comply with the trial procedures
- •History of alcohol dependence or drug abuse
- •Subjects whom the investigator (or sub-investigator) considers ineligible for the study
研究组 & 干预措施
GSK1358820 1.25 U (10-20 PD)
Active Comparator
Receive 1.25 U of GSK1358820 on Week 0
干预措施: GSK1358820 (Drug)
GSK1358820 2.5 U (10-20 PD)
Active Comparator
Receive 2.5 U of GSK1358820 on Week 0
干预措施: GSK1358820 (Drug)
GSK1358820 2.5 U (20-50 PD)
Active Comparator
Receive 2.5 U of GSK1358820 on Week 0
干预措施: GSK1358820 (Drug)
GSK1358820 5.0 U (20-50 PD)
Active Comparator
Receive 5.0 U of GSK1358820 on Week 0
干预措施: GSK1358820 (Drug)
结局指标
主要结局
Change From Baseline in Strabismus Angle Prism Dioptre (PD) in the Primary Position at Week 4 of the FTP in Observed Cases (OC)
时间窗: Baseline and Week 4 of the FTP
The strabismus angle in the primary position was measured using the alternative prism cover test (APCT). The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 meters \[m\]) and the near-view strabismus angle (measured at a distance of 33 centimeters \[cm\]). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. Change from Baseline was calculated as the value at Week 4 minus the value at Baseline.
次要结局
- Change From Baseline in the Strabismus Angle Prism Dioptre (PD) in the Primary Position at Week 1 After the Initial Injection of the FTP in Observed Cases (OC)(Baseline and Week 1 of the FTP)
- Change From Baseline in the Strabismus Angle PD in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 After the Final Injection of the FTP(Baseline and Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 after the final injection of the FTP)
- Change From Baseline in the Strabismus Angle PD in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, and 24 of the Second Treatment Period (STP)(Baseline and Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52))
- Absolute Strabismus Angle in the Primary Position at Weeks 1 and 4 of the FTP(Weeks 1 and 4 of the FTP)
- Absolute Strabismus Angle in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 After the Final Injection of the FTP(Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 after the final injection of the FTP)
- Absolute Strabismus Angle in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP(Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52))
- Percent Change From Baseline in the Strabismus Angle in the Primary Position at Week 1 and Week 4 in Observed Cases (OC) of the FTP(Baseline and Weeks 1 and 4 of the FTP)
- Percent Change From Baseline in the Strabismus Angle in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 After the Final Injection of the FTP(Baseline and Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 of the FTP)
- Percent Change From Baseline in the Strabismus Angle in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP(Baseline and Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52))
- Duration of Effect(Up to Week 48 after the final injection of the FTP (up to Study Week 52))
- Severity of Duction Limitation at Weeks 1 and 4 of the FTP(Week 1 and Week 4 of the FTP)
- Severity of Duction Limitation at Weeks 1, 4, 8, 12, 16, 20, and 24 After the Final Injection of the FTP(Weeks 1, 4, 8, 12, 16, 20, and 24 after the final injection of the FTP (up to a maximum of 52 weeks of the FTP))
- Severity of Duction Limitation at Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP(Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52))
- Change From Baseline in the Severity of Duction Limitation at Weeks 1 and 4 of the FTP(Baseline and Weeks 1 and 4 of the FTP)
- Change From Baseline in the Severity of Duction Limitation at Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 After the Final Injection of the FTP(Baseline and Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 after the final injection of the FTP (up to a maximum of 52 weeks of the FTP))
- Change From Baseline in the Severity of Duction Limitation at Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP(Baseline and Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary HyperhidrosisHyperhidrosisNCT01128738GlaxoSmithKline152
已完成
3 期
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb SpasticityPost-Stroke SpasticityCerebrovascular AccidentNCT00460564GlaxoSmithKline109
已完成
3 期
A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb SpasticitySpasticity, Post-StrokeNCT01205451GlaxoSmithKline109
已完成
3 期
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid AnalogueHepatitis B, ChronicNCT01480284GlaxoSmithKline166
已完成
2 期
Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With AsthmaAsthmaNCT01573624GlaxoSmithKline421